Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Many patients with obsessive-compulsive disorder do not respond adequately to serotonin reuptake inhibitors. Augmentation with antipsychotic drugs can be beneficial in this regard. However, since new relevant randomized controlled trials evaluating new antipsychotics were conducted, a recalculation of the effect sizes appears necessary. We meta-analyzed all double-blind, randomized, placebo-controlled trials comparing augmentation of serotonin reuptake inhibitors with antipsychotics to placebo supplementation in treatment-resistant obsessive-compulsive disorder. The primary outcome was mean change in the Yale-Brown Obsessive–Compulsive Scale total score. Secondary outcomes were obsessions, compulsions, response rates, and attrition rates. The data collection process was conducted independently by 2 authors. Hedges’s g and risks ratios were calculated as effect sizes. In preplanned meta-regressions, subgroup analyses, and sensitivity analyses, we examined the robustness of the results and explored reasons for potential heterogeneity. Altogether, 14 double-blind, randomized, placebo-controlled trials (n=491) investigating quetiapine (N=4, n=142), risperidone (N=4, n=132), aripiprazole (N=2, n=79), olanzapine (N=2, n=70), paliperidone (N=1, n=34), and haloperidol (N=1, n=34) were incorporated. Augmentation with antipsychotics was significantly more efficacious than placebo in Yale-Brown Obsessive–Compulsive Scale total reduction (N=14, n=478; Hedges’s g=-0.64, 95% CI: -0.87 to -0.41; P=<.01). Aripiprazole (Hedges’s g=-1.35), haloperidol (Hedges’s g=-0.82), and risperidone (Hedges’s g=-0.59) significantly outperformed placebo. Antipsychotics were superior to placebo in treating obsessions, compulsions, and achieving response. There was no between-group difference concerning all-cause discontinuation. The nonsignificant meta-regressions suggest no influence of the antipsychotic dose or baseline symptom severity on the meta-analytic results. According to our findings, antipsychotic augmentation of serotonin reuptake inhibitors can be regarded as an evidence-based measure in treatment-resistant obsessive-compulsive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5. Unrestricted maximum-likelihood meta-regression with mean olanzapine equivalents as continuous moderator variable. Hedges’s g refers to the effect sizes of the primary outcome (mean Yale–Brown Obsessive–Compulsive Scale [Y-BOCS] total score change). The olanzapine dose equivalents were calculated following the International Consensus Study of Antipsychotic Dosing (Gardner et al., 2010). The circle size reflects the weight a study obtained in this meta-regression. Slope=0.0002, 95% CI: -0.09 to 0.09; P=.996.](https://figures.cochat.ai/paper-figures/557e47f3e0974917a52a232803937ae6/antipsychotic-augmentation-of-serotonin-reuptake-inhibitors-in-treatment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whilst dopaminergic medications are not first-line treatments for OCD, dopamine receptor antagonists are often used to augment first-line treatment in refractory cases (Hirschtritt et al. 2017) and the efficacy of this strategy is confirmed by meta-analyses (Dold et al. 2015; Veale et al. 2014).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Dold et al. 2015
In the citing paper
“meta-analysis confirms that dopamine receptor antagonists reduce obsessive-compulsive symptoms in SSRI-refractory OCD (Dold et al. 2015; Veale et al. 2014).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Dold et al. 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“A potential publication bias was examined by funnel-plot visualization and accomplishment of Egger`s regression intercept test (2-tailed) (Egger et al., 1997).”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Haenszel random-effects model of Der-Simonian and Laired (Der-Simonian and Laird, 1986)”
MethodThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“…tic disorder (McDougle et al., 1994, 2000; Shapira et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005; Fineberg et al., 2005; Kordon et al., 2008; Simpson et al., 2013) did not alter the combined overall effect sizes in terms of statistical significance (N = 6, n = 195; Hedges’s g =…”
BackgroundA Fail-Safe N for Effect Size in Meta-Analysis
Orwin, R. G. (1983) · Journal of Educational Statistics · doi:10.2307/1164923 · Cited by 2,064 · cited 1×
“Moreover, we estimated the number of negative unpublished trials (fail-safe N value) that would be necessary to dissolve statistically significant differences (Orwin, 1983).”
BackgroundInternational Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301 · cited 3×
“In unrestricted maximum-likelihood meta-regression analyses, we investigated the impact of the continuous moderators: (1) mean administered antipsychotic dose (calculated as olanzapine equivalents according to the International Consensus Study of Antipsychotic Dosing [Gardner et al., 2010]); and (2) baseline symptom s…”
MethodInfluentialKahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Research works printed but not linked: 2
- Borenstein, 2006, Comprehensive meta-analysis, version 2
- The Cochrane Collaboration, 2014, Review Manager (RevMan) [Computer program]. Version 5.3
Cited by
Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
“0b013e318185e735] [PMID: 18794652] [148] Dold, M.”
BackgroundInfluentialFineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
“…there is randomized controlled trial (RCT) and meta-analytic evidence to support augmentation with an second-generation antipsychotic (Brakoulias and Stockings, 2019; Dold et al., 2015; Stein et al., 2012; Zhou et al., 2019); however, the use of these agents would be considered off-label.”
BackgroundClinical practice guidelines for Obsessive-Compulsive Disorder
Janardhan Reddy, Y., Sundar, A., Narayanaswamy, J., & Math, S. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196976 · Cited by 156
Kim, S. J., Roh, D., Jung, H. H., Chang, W. S., Kim, C.-H., & Chang, J. W. (2018) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.170188 · Cited by 121
Obsessive-compulsive disorder in children and adolescents: epidemiology, diagnosis and management
Nazeer, A., Latif, F., Mondal, A., Azeem, M. W., & Greydanus, D. E. (2020) · Translational Pediatrics · doi:10.21037/tp.2019.10.02 · Cited by 129
“While efficacy has been demonstrated in adults (158,159), this has not been evaluated systematically in the pediatric population aside from case series and open trials.”
BackgroundTreatment-resistant OCD: Pharmacotherapies in adults
van Roessel, P. J., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Van Ameringen, M., & Rodríguez, C. I. (2023) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152352 · Cited by 86
Albert, U., Marazziti, D., Di Salvo, G., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666171222163645 · Cited by 90
Obsessive–compulsive disorder comorbid with schizophrenia and bipolar disorder
Reddy, Y. C. J., & Sharma, L. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_527_18 · Cited by 84
“in augmenting the action of selective serotonin reuptake inhibitors (SSRIs) in treating OCD[52] and higher doses causing emergence of OCS.”
BackgroundSwierkosz-Lenart, K., dos Santos, J. F. A., Elowe, J., Clair, A., Bally, J., Riquier, F., Bloch, J., Draganski, B., Clerc, M.-T., Moyano, B. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1065812 · Cited by 58
“The overall rate of attrition in the group treated with antipsychotics as add-ons ranged from 10 to 25%, attributable in part to adverse effects, the main ones reported being mouth dryness, headache, and increased appetite (36).”
BackgroundPharmacotherapeutic Strategies and New Targets in OCD
Pittenger, C. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_204 · Cited by 58
Murray, G. K., Knolle, F., Ersche, K. D., Craig, K. J., Abbott, S., Shabbir, S. S., Fineberg, N. A., Suckling, J., Sahakian, B. J., Bullmore, E. T., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05292-2 · Cited by 53
Arumugham, S. S., VS, S., HN, M., B, V., Ravi, M., Sharma, E., Thirthalli, J., & Reddy, Y. J. (2018) · The Journal of ECT · doi:10.1097/yct.0000000000000509 · Cited by 50
“Treatment with augmenting drugs like atypical antipsychotics has been found to be effective in around 30 % of these patients.(3) Invasive treatments like deep brain stimulation and ablative neurosurgery, which may be helpful in severe and intractable patients, are associated with significant adverse effects.”
Pardossi, S., Cuomo, A., & Fagiolini, A. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164739 · Cited by 51
“Partial agonist antipsychotics also show promise, despite the lack of extensive controlled studies for the treatment of OCSs [107–109].”
BackgroundLaroche, D. G., & Gaillard, A. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.09.031 · Cited by 48
“Many antipsychotics are effective with typical OCD, even when it is refractory to SSRIs (Dold et al., 2015, Veale et al., 2014), but they can cause induced OCS or OCD in schizophrenia patients under treatment (Simon et al., 2006, Ramasubbu, 2002, Mahendran et al., 2007, Tranulis et al., 2005).”
Gerasch, S., Kanaan, A. S., Jakubovski, E., & Müller‐Vahl, K. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00416 · Cited by 47
Zhou, D., Zhou, X., Li, Y., Zhang, K.-F., Lv, Z., Chen, X., Wan, L.-Y., Wang, W., Wang, G.-M., Li, D., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.009 · Cited by 48
Scheepers, I. M., Cryan, J. F., Bastiaanssen, T. F. S., Rea, K., Clarke, G. A., Jaspan, H. B., Harvey, B. H., Hemmings, S. M. J., Santana, L., van der Sluis, R., et al. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14610 · Cited by 45
Psychopharmacotherapy of Obsessive-Compulsive Symptoms within the Framework of Tourette Syndrome
Rothenberger, A., & Roessner, V. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180828095131 · Cited by 41
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap
Szechtman, H., Harvey, B. H., Woody, E. Z., & Hoffman, K. L. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017772 · Cited by 41
“Subsequent meta-analyses that included additional trials confirmed the efficacy of neuroleptic augmentation in treatment-resistant OCD (Skapinakis et al., 2007; Dold et al., 2013, 2015; Veale et al., 2014).”
BackgroundResultObsessive-Compulsive Disorders
Mathews, C. (2021) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001011 · Cited by 39
A randomized controlled study of brief family-based intervention in obsessive compulsive disorder
Baruah, U., Pandian, R. D., Narayanaswamy, J. C., Math, S. B., Thennarasu, K., & Reddy, Y. C. J. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.08.014 · Cited by 38
Kim, M., Kwak, S., Yoon, Y. B., Kwak, Y. B., Kim, T., Cho, K. I. K., Lee, T. Y., & Kwon, J. S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0436-2 · Cited by 37
Kim, D., Ryba, N., Kalabalik, J., & Westrich, L. (2018) · Drugs in R&D · doi:10.1007/s40268-018-0246-8 · Cited by 38
“There were overall significantly more adverse effects in the antipsychotic treatment group compared with placebo group, although the discontinuation rate did not differ between the groups [120].”
ResultZhou, D.-D., Zhou, X.-X., Lv, Z., Chen, X.-R., Wang, W., Wang, G.-M., Liu, C., Li, D.-Q., & Kuang, L. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.014 · Cited by 37
The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder?
Kayser, R. R., Snorrason, I., Haney, M., Lee, F. S., & Simpson, H. B. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0049 · Cited by 35
Antipsychotic augmentation in the treatment of obsessive-compulsive disorder
Jaisoorya, T. S., & Thamby, A. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_519_18 · Cited by 39
“There are six meta-analyses to date, all of which have included double-blind, randomized, placebo-controlled trials comparing augmentation of SSRIs with antipsychotics to placebo supplementation in treatment-resistant OCD.”
BackgroundResultInfluentialManagement and treatment of obsessive–compulsive disorder
Fineberg, N. A., Drummond, L. M., Reid, J. E., Cinosi, E., Carmi, L., & Mpavaenda, D. (2020) · doi:10.1093/med/9780198713005.003.0098 · Cited by 33
Therapeutic D evelopments for T ics and M yoclonus
Jankovic, J. J. (2015) · Movement Disorders · doi:10.1002/mds.26414 · Cited by 33
“It is beyond the scope of this article to review all therapies of behavioral comorbidities associated with TS, but the reader is referred to some recent reviews of therapeutic strategies used for ADHD(9-11) and OCD.(12,13)”
MethodTrichotillomania is more related to Tourette disorder than to obsessive-compulsive disorder
Lamothe, H., Baleyte, J., Mallet, L., & Pélissolo, A. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0471 · Cited by 37
The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders
Pignon, B., du Montcel, C. T., Carton, L., & Pélissolo, A. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0847-x · Cited by 35
Ablative neurosurgery and deep brain stimulation for obsessive-compulsive disorder
Arumugham, S. S., Balachander, S., & Srinivas, D. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_523_18 · Cited by 31
“[4,5] Around 30% of such patients respond to augmentation with antipsychotics.[6,7] It has been estimated that around 10%–20% of OCD patients are refractory to all available pharmacological and psychological treatments.”
BackgroundObsessive–Compulsive Disorder in Autism Spectrum Disorder Across the Lifespan
Pazuniak, M., & Pekrul, S. R. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2019.12.003 · Cited by 32
Management of Treatment-Resistant Obsessive-Compulsive Disorder
Gershkovich, M., Wheaton, M. G., & Simpson, H. B. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0127-8 · Cited by 32
Suhas, S., Malo, P. K., Kumar, V., Issac, T. G., Chithra, N. K., Bhaskarapillai, B., Reddy, Y. C. J., & Rao, N. P. (2022) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2082525 · Cited by 31
“2022 Informa UK Limited, trading as Taylor & Francis Group et al. 2013; Veale et al. 2014; Dold et al. 2015), memantine (Modarresi et al. 2018), and D-Cycloserine (Xia et al. 2015; McGuire et al. 2017).”
BackgroundClozapine-induced obsessive–compulsive symptoms: mechanisms and treatment
Kim, D. D., Barr, A. M., White, R. F., Honer, W. G., & Procyshyn, R. M. (2018) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.180087 · Cited by 28
Biria, M., Cantonas, L.-M., & Banca, P. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_201 · Cited by 27
The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder
Escobar, A. P., Wendland, J., Chávez, A., & Moya, P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01362 · Cited by 19
The Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.11.005 · Cited by 28
Ketamine induces immediate and delayed alterations of OCD-like behavior
Thompson, S. L., Welch, A. C., Iourinets, J., & Dulawa, S. C. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05397-8 · Cited by 24
“Augmenting SRI treatment with atypical antipsychotics has proven effective in some treatment-refractory patients (Veale et al. 2014; Dold et al. 2015) but with the downside of associated side effects.”
BackgroundSahraian, A., Ehsaei, Z., & Mowla, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.014 · Cited by 23
Burk, B. G., DiGiacomo, T., Polancich, S., Pruett, B. S., Sivaraman, S., & Birur, B. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13567 · Cited by 25
“In more recent meta-analyses, aripiprazole has also been shown to have significant impact on OCD symptoms.(12,48,49) Of note, Zhou et al.”
BackgroundPittenger, C., Brennan, B. P., Koran, L. M., Mathews, C. A., Nestadt, G., Pato, M. T., Phillips, K. A., Rodríguez, C. I., Simpson, H. B., Skapinakis, P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113853 · Cited by 24
Treatment Resistance in Obsessive-Compulsive Disorder
Middleton, R., Wheaton, M. G., Kayser, R., & Simpson, H. B. (2019) · Treatment Resistance in Psychiatry · doi:10.1007/978-981-10-4358-1_11 · Cited by 19
Marincowitz, C., Koen, N., Löchner, C., & Stein, D. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00012-5 · Cited by 19
A closer look to neural pathways and psychopharmacology of obsessive compulsive disorder
Gargano, S. P., Santos, M. G., Taylor, S. M., & Pastis, I. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1282246 · Cited by 18
Akbari, M., Jamshidi, S., Sheikhi, S., Alijani, F., Kafshchi, P., & Taylor, D. M. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06529-5 · Cited by 18
“Finally, although there are studies that show some efficacy for ARI as an augmenting agent for obsessive–compulsive symptoms (for example, Dold et al. 2015; Thamby & Jaisoorya 2019), there are also contradictory reports of obsessive–compulsive symptoms and/or disorder being associated with ARI or…”
Poppe, C., Müller, S. T., Greil, W., Walder, A., Grohmann, R., & Stübner, S. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.035 · Cited by 19
“For FGAs there is only evidence for haloperidol in the treatment of OCD, especially in the case of obsessions and comorbid ticdisorder (Bloch et al., 2006; Dold et al., 2015; Komossa et al., 2010; Li et al., 2005).”
BackgroundInfluentialMartiadis, V., Pessina, E., Martini, A., Raffone, F., Cattaneo, C. I., Berardis, D. D., & Pampaloni, I. (2024) · CNS Spectrums · doi:10.1017/s1092852924000348 · Cited by 19
“…examined, although the results are inconsistent and multiple meta-analyses have been unable to demonstrate their superiority versus placebo 5,9 – 11 ; paliperidone has been studied in treatment-resistant OCD patients in one randomized, placebo-controlled trial of 8 weeks showing significant…”
Woody, E. Z., Hoffman, K. L., & Szechtman, H. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.04.003 · Cited by 17
The use of antipsychotics in obsessive compulsive disorder
Conti, D., Girone, N., Boscacci, M., Casati, L., Cassina, N., Cerolini, L., Giacovelli, L., Viganò, C. A., Conde, M. M., Cremaschi, L., et al. (2024) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2893 · Cited by 15
“However, other meta ‐ analyses did not report a significant efficacy for quetiapine compared with placebo (Dold et al., 2015; Savas et al., 2008).”
BackgroundResultInfluentialPoyurovsky, M., Braverman, L., & Weizman, A. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000325 · Cited by 16
Hoffman, K. L., & Cano-Ramírez, H. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1417379 · Cited by 18
“be superior to placebo, with aripiprazole, haloperidol, and risperidone showing the most robust effects, and smaller (trend) effects for olanzapine and quetiapine [71].”
BackgroundDell’Osso, B. M., Vismara, M. E. M., Benatti, B., Cirnigliaro, G., Grancini, B. M., Fineberg, N. A., Ameringen, M. V., Hollander, E., Stein, D. J., Menchón, J. M., et al. (2019) · CNS Spectrums · doi:10.1017/s1092852919001068 · Cited by 17
Obsessive–Compulsive Disorder in Autism Spectrum Disorder Across the Lifespan
Pazuniak, M., & Pekrul, S. R. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.08.010 · Cited by 15
Ameringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 14
Psilocybin in pharmacotherapy of obsessive-compulsive disorder
Owe-Larsson, M., Kamińska, K., Buchalska, B., Mirowska-Guzel, D. M., & Cudnoch‐Jędrzejewska, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00633-1 · Cited by 15
“Antipsychot - ics such as aripiprazole, haloperidol, and risperidone, turned out to be more effective than placebo in the treatment of OCD, according to a meta-analysis [106 ].”
MethodLounici, A., Iacob, A., Hongler, K., Mölling, M. A., Drechsler, M., Hersberger, L., Sethi, S., Lang, U. E., & Liwinski, T. (2024) · Nutrients · doi:10.3390/nu17010031 · Cited by 14
Zhu, R., Dong, X., Zhang, D., Liu, X., Ye, Y., & Jiang, Y. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa085 · Cited by 14
Shared genetic loci and causal relations between schizophrenia and obsessive-compulsive disorder
Chen, Y., Guo, H., & Yue, W. (2023) · Schizophrenia · doi:10.1038/s41537-023-00348-x · Cited by 13
Kishi, T., Sakuma, K., & Iwata, N. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02026-5 · Cited by 13
de Oliveira, M. V. S., de Barros, P. M. F., de Mathis, M. A., Boavista, R., Chacon, P., Echevarria, M. A. N., Ferrão, Y. A., Vattimo, E. F. D. Q., Lopes, A. C., Torres, A. R., et al. (2023) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2022-2891 · Cited by 50
A pilot study of magnetic seizure therapy for treatment‐resistant obsessive–compulsive disorder
Tang, V. M., Blumberger, D. M., Weissman, C. R., Dimitrova, J., Throop, A., McClintock, S. M., Voineskos, D., Rajji, T. K., Downar, J. H., Knyahnytska, Y., et al. (2020) · Depression and Anxiety · doi:10.1002/da.23097 · Cited by 14
“The most well‐established option for treatment‐ resistant OCD is the augmentation of an SRI with an antipsychotic; however, only approximately one‐third of patients prescribed this combination will respond (Dold et al., 2015).”
BackgroundHegde, A., Kalyani, B. G., Arumugham, S. S., Narayanaswamy, J. C., Math, S. B., & Reddy, Y. C. J. (2016) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1225098 · Cited by 12
“2014) or failed to report a definite association between dose and response (Dold et al. 2015).”
BackgroundResultInfluentialSijercic, I., Whitfield, K. M., Cassin, S. E., & Antony, M. M. (2020) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2020.100532 · Cited by 12
Obsessive-compulsive disorder – A state-of-the-art review
Endres, D., Schiele, M. A., von Zedtwitz, K., Dressle, R. J., Maier, A., Hohagen, F., Baldermann, J. C., Coenen, V. A., Jelinek, L., Domschke, K., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106320 · Cited by 11
Mazzoleni, A., Bhatia, S., Bantounou, M. A., Kumar, N. S., Dzalto, M., & Soiza, R. L. (2023) · BJPsych Open · doi:10.1192/bjo.2023.539 · Cited by 11
Lai, J., Lu, Q., Zhang, P., Xu, T., Xu, Y., & Hu, S. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s122316 · Cited by 9
Jalenques, I., Asatryan, V., Tauveron-Jalenques, U., Pereira, B., & Rondepierre, F. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.09.048 · Cited by 9
Clinical practice guidelines for obsessive-compulsive disorder: 2025 update
Arumugham, S. S., Narayanaswamy, J. C., Balachander, S., Sharma, E., Jaisoorya, T. S., Reddy, S. C., Siddiqui, A., Desouza, A., Shah, P., & Reddy, Y. C. J. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_1259_25 · Cited by 13
“[45,64] About a third of patients respond to antipsychotic augmentation.”
InfluentialHatakama, H., Asaoka, N., Nagayasu, K., Shirakawa, H., & Kaneko, S. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108926 · Cited by 9
Dold, M., Bartova, L., Souery, D., Mendlewicz, J., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., & Kasper, S. F. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.033 · Cited by 9
Self-citationGiacovelli, L., Piccoli, E., Landi, P., Vismara, M. E. M., Benatti, B., & Dell’Osso, B. M. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000583 · Cited by 8
Amerio, A., Odone, A., & Ghaemi, S. N. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.024 · Cited by 8
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Park, C. I., Han, M., Jung, I., Kim, E. H., Kang, J. I., & Kim, S. J. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13375 · Cited by 7
Baweja, R. K., Waschbusch, D. A., Rajalakshmi, A. K., Petrovic-Dovat, L., & Waxmonsky, J. G. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2025.0049 · Cited by 6
Gupta, P., Gupta, R., & Balhara, Y. P. S. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000629 · Cited by 6
Moving beyond first-line treatment options for OCD
Paxos, C. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.10.300 · Cited by 6
Brexpiprazole as a new approach of treatment in somatization disorder
Chiappini, S., Mosca, A., Martinotti, G., Carlo, F. D., Miuli, A., Dattoli, L., Pettorruso, M., & Giannantonio, M. D. (2022) · Emerging Trends in Drugs Addictions and Health · doi:10.1016/j.etdah.2022.100031 · Cited by 6
Hegde, A., Kalyani, B. G., Arumugham, S. S., Narayanaswamy, J. C., Math, S. B., & Reddy, Y. C. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000515 · Cited by 6
“Treatment adherence may improve with a less sedating and metabolic-neutral antipsychotic like aripiprazole, which has been found to be effective for augmentation in 2 RCTs.(10) We were unable to find any significant predictors of response for risperidone augmentation.”
BackgroundResultInfluentialAre current pharmacotherapeutic strategies effective in treating OCD?
Reddy, Y. C. J., & Arumugham, S. S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1735355 · Cited by 5
Poyurovsky, M., & Weizman, A. (2021) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000456 · Cited by 4
“This is in contrast to the lack of quetiapine's efficacy in patients with “pure” OCD resistant to SSRIs, as revealed in recent meta-analyses.(13,14) It is plausible that quetiapine's therapeutic utility in patients with OCD is restricted to those with comorbid bipolar disorder, particularly BP-D episode.”
ResultWeidle, B., Ivarsson, T., Asbahr, F. R., Calvo, R. M., Mataix‐Cols, D., Rynn, M. A., & Storch, E. A. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113858 · Cited by 4
Obsessive‐compulsive disorder: current management options
Harris, P. G., Drummond, L. M., & Fineberg, N. A. (2019) · Prescriber · doi:10.1002/psb.1793 · Cited by 5
Rosso, G., PERACCHIA, S., Pesci, N. R., Salvo, G. D., & Maina, G. (2026) · Biomedicines · doi:10.3390/biomedicines14010179 · Cited by 3
Montoya, B., Lazar, H., & Fleishman, K. (2025) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000847 · Cited by 3
Zai, G. C., Zai, C. C. H., Burroughs, E., Arnold, P. D., Kennedy, J. L., & Richter, M. A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111428 · Cited by 3
Cavanna, A. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816563-8.00003-6 · Cited by 4
Obsessive-Compulsive Disorder (OCD)
Ehret, M. J. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.ocd_overview · Cited by 3
Marmureanu, M., Besoiu, M. V., Dionisie, V., Manea, M., Pleșea-Condratovici, C., Voican, S. I., & Manea, M. (2026) · Pharmaceuticals · doi:10.3390/ph19040628 · Cited by 2
“Its clinical utility is further constrained by tolerability issues, such as metabolic and extrapyramidal side effects [2,3].”
Clinical utility of trifluoperazine in the treatment of obsessive-compulsive disorder: A case report
Chithra, N. K., Suhas, S., Sreeraj, V. S., & Venkatasubramanian, G. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2022.103051 · Cited by 1
Chapter 52. Treatment of Obsessive-Compulsive Disorder
Kayser, R. R., & Simpson, H. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as52 · Cited by 1
Sugawara, T., & Ichiki, R. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70148 · Cited by 1
“16 It is possible that the neuroimmune changes induced by SARS ‐ COV ‐ 2 also influenced the dopamine system, resulting in increased dopamine activity.”
Pöppel, S., Ziegler, S., Bednasch, K., Kohls, E., & Rummel‐Kluge, C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1642622 · Cited by 2
Shahtou, A., Omara, H. R., Qari, S. A., Alqahtani, R. S., Alnasyan, Z. S., Alotaibi, A. E., Ali, A. A., Alabdulrahim, J. M., Naser, S. A., Asad, N., et al. (2026) · Cureus · doi:10.7759/cureus.108358 · Cited by 1
“…meta-analyses (NMAs) have demonstrated the superior efficacy of specific antipsychotics, most notably risperidone, aripiprazole, and haloperidol, over placebo in reducing OCD symptom severity, with approximately one-third of refractory patients achieving a clinically meaningful response [22-25].”
Özsoy, F., Tasci, G., Taşçı, B., Doğan, Ş., & Tuncer, T. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.118161 · Cited by 1
Novel trends in treatment of obsessive-compulsive disorder
Stopková, P. (2017) · Psychiatrie pro praxi · doi:10.36290/psy.2017.021 · Cited by 1
Drugs to Treat Anxiety and Insomnia
Baldwin, D. S., & Huneke, N. T. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.010 · Cited by 1
McCutcheon, R. A., Kaar, S. J., & Howes, O. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.011 · Cited by 1
Metadata
- Authors
- Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S.
- Affiliations
- Universitätsklinikum Tulln (AT)
- Corresponding author
- Kasper, Siegfried
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-04
- Volume
- 18
- Issue
- 9
- Pages
- pyv047
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4576518
- OpenAlex
- W4244844159
- Cited by
- 134
- References
- 49
- Citations by year
- 2026: 19 · 2025: 11 · 2024: 16 · 2023: 7 · 2022: 8 · 2021: 12 · 2020: 16 · 2019: 16 · 2018: 10 · 2017: 11 · 2016: 7 · 2015: 1
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Servier
- H. Lundbeck A/S
- Cilag
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- treatment-resistant OCD, antipsychotic augmentation, serotonin reuptake inhibitors, quetiapine, risperidone, aripiprazole, olanzapine, paliperidone, haloperidol, Yale-Brown Obsessive Compulsive Scale, obsessions and compulsions, treatment response, attrition, antipsychotic dosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.